Spectrum Pharmaceuticals Announces Submission of Biologics License Application to the FDA for ROLONTIS
pharmaceutical investing Spectrum Pharmaceuticals Presents ADVANCE Phase 3 ROLONTIS (eflapegrastim) Data
NextSource Materials Signs Agreement for the Supply of Graphite Fines as Additional Source of Feedstock for its Battery Anode Facility in Abu Dhabi
